GTBP insider filings

GT Biopharma, Inc. — 29 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-09-08. Screen GTBP transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for GTBP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — GT Biopharma, Inc.

FiledFormInsiderReported transactionsSource
2025-09-084URBAN ALAN LOUIS — Chief Financial OfficerGrant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2025-09-084Mun-Gavin David C. — DirectorGrant/award (A): 31,250 (derivative) @ $0EDGAR
2025-09-084Kramer Hilary — DirectorGrant/award (A): 31,250 (derivative) @ $0EDGAR
2025-09-084CASAMENTO CHARLES J — DirectorGrant/award (A): 62,500 (derivative) @ $0EDGAR
2025-09-084Breen Michael Martin — CEO and Director, DirectorGrant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR
2024-10-214URBAN ALAN LOUIS — Chief Financial OfficerGrant/award (A): 23,335 (derivative) @ $0EDGAR
2023-08-154Breen Michael Martin — Executive Chairman/Interim CEO, DirectorGrant/award (A): 200,000 @ $0.29EDGAR
2023-08-154Ohri Manu — CFO & SecretaryGrant/award (A): 200,000 @ $0.29 · Other (J): 200,000 @ $0.29 · Other (J): 200,000 @ $0.29EDGAR
2023-06-214CASAMENTO CHARLES J — DirectorGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-04-114Breen Michael Martin — Executive Chairman/Interim CEO, DirectorPurchase (P): 50,000 @ $0.50EDGAR
2023-04-104Ohri Manu — CFO & SecretaryPurchase (P): 50,000 @ $0.50EDGAR
2023-02-014Breen Michael Martin — Exec Chairman and Interim CEO, DirectorGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-02-014Ohri Manu — Chief Financial OfficerGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-02-014SHROTRIYA RAJESH C MD — DirectorGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-02-014Wendel Bruce — DirectorGrant/award (A): 500,000 (derivative) @ $0EDGAR
2022-07-194Breen Michael Martin — Exec. Chair. and Interim CEO, DirectorGrant/award (A): 278,058 @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2022-07-194SHROTRIYA RAJESH C MD — DirectorGrant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 361,476 (derivative) @ $0EDGAR
2022-07-194URBAN ALAN LOUIS — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2022-07-194Berk Gregory — Pres. of R&D, CMOGrant/award (A): 50,000 (derivative) @ $0EDGAR
2022-07-194Ohri Manu — CFO & SecretaryGrant/award (A): 100,000 @ $0 · Other (J): 100,000 @ $0 · Other (J): 100,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0EDGAR
2022-07-194Wendel Bruce — DirectorGrant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2022-02-144Berk Gregory — DirectorGrant/award (A): 278,058 @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2022-02-144SHROTRIYA RAJESH C MD — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2022-02-144Choy Gavin — Acting Chief Financial OfficerGrant/award (A): 227,500 (derivative) @ $0EDGAR
2021-11-124Breen Michael Martin — DirectorGrant/award (A): 278,058 @ $0 · Conversion (C): 40,243 @ $3.40 · Conversion (C): 9,859 @ $3.40 · Grant/award (A): 50,000 (derivative) @ $0 · Conversion (C): 100,000 (derivative) @ $0 · Conversion (C): 30,000 (derivative) @ $0EDGAR
2021-10-074Wendel Bruce — DirectorPurchase (P): 3,268 @ $3.14 · Purchase (P): 1,374 @ $8.87 · Purchase (P): 441 @ $8.73 · Grant/award (A): 347,572 @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2020-12-234Weldon Steven WSale (S): 50,000 @ $0.30 · Sale (S): 50,000 @ $0.33 · Sale (S): 35,722 @ $0.34 · Sale (S): 47,978 @ $0.40EDGAR
2020-12-184Weldon Steven WSale (S): 50,000 @ $0.30 · Sale (S): 50,000 @ $0.30 · Sale (S): 50,000 @ $0.31 · Sale (S): 50,000 @ $0.30EDGAR
2020-12-154Weldon Steven WSale (S): 50,000 @ $0.25 · Sale (S): 50,000 @ $0.26 · Sale (S): 50,000 @ $0.28 · Sale (S): 50,000 @ $0.29 · Sale (S): 46,300 @ $0.29 · Sale (S): 50,000 @ $0.30 · +2 moreEDGAR

Recent 8-K events — GT Biopharma, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-128-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-258-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-218-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-158-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-038-K3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-148-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-128-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-228-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-078-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-028-K4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — GT Biopharma, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=GTBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs